1. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
   L E Anselmino et al, 2021, Sci Rep CrossRef
2. A GLUT1 Inhibitor-Based Fluorogenic Probe for Warburg Effect-Targeted Drug Screening and Diagnostic Imaging of Hyperglycolytic Cancers
   Shunjie Zhang et al, 2021, Analytica Chimica Acta CrossRef
3. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
   Dey Nandini et al, 2021, Pharmaceuticals CrossRef
4. NIR Fluorescent Imaging and Photodynamic Therapy with a Novel Theranostic Phospholipid Probe for Triple-Negative Breast Cancer Cells
   Natalia I. Rubtsova et al, 2021, Bioconjugate Chem. CrossRef
5. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs.
   Qitong Wu et al, 2021, Cancers (Basel) CrossRef
6. An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer
   Narges Dastmalchi et al, 2021, Expert Review of Molecular Diagnostics CrossRef
7. Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human
   Weipeng Zhao et al, 2021, Front. Cell Dev. Biol. CrossRef
8. PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
   Wen-Jing Hsu et al, 2021, JPM CrossRef
9. Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer
   Fokhrul Hossain et al, 2021, Nutrients CrossRef
10. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
    Nayanendu Saha et al, 2022, Translational Oncology CrossRef
11. Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A
    Hung-Yu Lin et al, 2022, Biomedicine & Pharmacotherapy CrossRef
12. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer
    Diaaeldin M. Elimam et al, 2022, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
13. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
    Enrica Balza et al, 2022, Cancer Medicine CrossRef
14. Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells
    Yu-Ting Yen et al, 2021, IJMS CrossRef
15. Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules
    Rossana Galassi et al, 2022, Biomolecules CrossRef
16. Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes
    Christopher Wittmann et al, 2022, Inorg. Chem. CrossRef
17. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics
    Janice Jacson Mandumpala et al, 2022, Life Sciences CrossRef
18. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
    Frederic St-Denis-Bissonnette et al, 2022, Cancers CrossRef
19. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer
    Hagen Sjard Bachmann et al, 2022, Cancers CrossRef
20. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Ian Landry et al, 2022, Cureus CrossRef
21. Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
    Marta Marqués et al, 2022, Cancers CrossRef
22. Low-risk triple-negative breast cancers: clinico-pathological and molecular features
    Nicola Fusco et al, 2022, Critical Reviews in Oncology/Hematology CrossRef
23. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers
    Chi-Cheng Huang et al, 2022, Ann Surg Oncol CrossRef
24. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
    Ruoning Yang et al, 2022, Mol Biomed CrossRef
25. Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles
    Luis Exequiel Ibarra et al, 2022, Pharmaceutics CrossRef
26. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database
    Zhuowei Tang et al, 2022, Front. Endocrinol. CrossRef
27. The Value of Shear Wave Elastography in the Diagnosis of Breast Cancer Axillary Lymph Node Metastasis and Its Correlation With Molecular Classification of Breast Masses
    Changyun Luo et al, 2022, Front. Oncol. CrossRef
28. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
    Juan Carlos Montero et al, 2022, J Exp Clin Cancer Res CrossRef
29. Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics
    Amiya Das et al, 2022, ACAMC CrossRef
30. Cinobufacini Injection Inhibits the Proliferation of Triple-Negative Breast Cancer Through the Pin1–TAZ Signaling Pathway
    Lu Kong et al, 2022, Front. Pharmacol. CrossRef
31. The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis
    Yuyan Huang et al, 2022, Clin Exp Med CrossRef
32. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC
    Ha Rin Kim et al, 2022, Journal of Controlled Release CrossRef
33. Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
    Aiswarya Chaudhuri et al, 2022, Pharmaceuticals CrossRef
34. PD-L1 expression in Congolese women with triplenegative breast cancer
    Olivier Mukuku et al, 2022, JCPCR CrossRef
35. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Fei Yang et al, 2022, Bioorganic & Medicinal Chemistry CrossRef
36. Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape
    Xuemei Xie et al, 2022, Expert Opinion on Therapeutic Targets CrossRef
37. Prediction of Treatment Response in Triple Negative Breast Cancer From Whole Slide Images
    Peter Naylor et al, 2022, Front. Signal Process. CrossRef
38. Ceritinib is a novel triple negative breast cancer therapeutic agent
    Shengli Dong et al, 2022, Mol Cancer CrossRef
39. Discovery of novel acridine-chalcone hybrids with potent DNA binding and antiproliferative activity against MDA-MB-231 and MCF-7 cells
    Mária Vilková et al, 2022, Med Chem Res CrossRef
40. Surgical Efficacy and Prognosis of 54 Cases of Spinal Metastases from Breast Cancer
    Yao Weitao et al, 2022, World Neurosurgery CrossRef
41. Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression
    Hsin-Yi Chen et al, 2022, J Hematol Oncol CrossRef
42. Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Min Huang et al, 2022, Immunotherapy CrossRef
43. Coactosin-Like Protein in Breast Carcinoma: Friend or Foe?
    Bei Wang et al, 2022, JIR CrossRef
44. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    S. Michaleas et al, 2022, ESMO Open CrossRef
45. Association of Pathway Mutations With Survival in Taiwanese Breast Cancers
    Po-Sheng Yang et al, 2022, Front. Oncol. CrossRef
46. Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis
    Huilin Yang et al, 2022, Molecular Therapy CrossRef
47. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
    Fan Yang et al, 2022, Cell Biol Int CrossRef
48. Extracellular vesicles derived from Wharton’s Jelly mesenchymal stem cells inhibit the tumor environment via the miR-125b/HIF1α signaling pathway
    Yun-Hsuan Chang et al, 2022, Sci Rep CrossRef
49. Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
    Malvina Koni et al, 2022, Cancers CrossRef
50. LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells
    Li Pan et al, 2022, Biomedicines CrossRef
51. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
    Shengyu Pu et al, 2022, Front. Immunol. CrossRef
52. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
    Rita Ribeiro et al, 2022, Front. Mol. Biosci. CrossRef
53. Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
    Marek Z. Wojtukiewicz et al, 2022, Cancer Metastasis Rev CrossRef
54. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression
    Esraa Magdy Abdelraouf et al, 2022, Life Sciences CrossRef
55. 99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer
    Buhui Yu et al, 2022, Front. Bioeng. Biotechnol. CrossRef
56. The Present and Future of Clinical Management in Metastatic Breast Cancer
    Pauline H. Lin et al, 2022, JCM CrossRef
57. Isobavachalcone Induces Multiple Cell Death in Human Triple-Negative Breast Cancer MDA-MB-231 Cells
    Cheng-Zhu Wu et al, 2022, Molecules CrossRef
58. Platelet-Derived Extracellular Vesicles Stimulate Migration through Partial Remodelling of the Ca2+ Handling Machinery in MDA-MB-231 Breast Cancer Cells
    Mauro Vismara et al, 2022, Cells CrossRef
59. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming
    Hassan Yousefi et al, 2022, Oncogene CrossRef
60. Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer
    Yanhui Zhu et al, 2022, Cancer Medicine CrossRef
61. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer
    Xiaorui Sun et al, 2022, Front. Genet. CrossRef
62. Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrier
    Xin Liu et al, 2022, Clin Exp Metastasis CrossRef
63. Tumor-Derived Exosomes and Their Role in Breast Cancer Metastasis
    Shaojuan Huang et al, 2022, IJMS CrossRef
64. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
    Eva Kudelova et al, 2022, IJMS CrossRef
65. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair
    Shu-Ping Wang et al, 2021, Cell Death Dis CrossRef
66. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer
    Soyoung Kim et al, 2022, IJMS CrossRef
67. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
    Avinash Khadela et al, 2022, Med Oncol CrossRef
68. A Novel Prognostic Prediction Model Based on Pyroptosis-Related Clusters for Breast Cancer
    Baoxing Tian et al, 2022, JPM CrossRef
69. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
    Boya Lu et al, 2023, Technol Cancer Res Treat CrossRef
70. HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple‑negative breast cancer
    Mengdi Zhu et al, 2022, Oncol Lett CrossRef
71. Highly Metastatic Subpopulation of TNBC Cells Has Limited Iron Metabolism and Is a Target of Iron Chelators
    Yuze Wang et al, 2023, Cancers CrossRef
72. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling
    Yuqi Liang et al, 2023, DDDT CrossRef
73. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions
    Leilei Fu et al, 2023, Biochemical Pharmacology CrossRef
74. Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Jinlin Zhang et al, 2023, European Journal of Medicinal Chemistry CrossRef
75. Dysfunction of the ST7-AS1/miR-301b-3p/BTG1 ceRNA network promotes immune escape of triple-negative breast cancer
    Yong Li et al, 2023, International Immunopharmacology CrossRef
76. A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
    Xiangdi Meng et al, 2023, Front. Endocrinol. CrossRef
77. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: a preliminary study
    Sylwia Michlewska et al, 2023, International Journal of Pharmaceutics CrossRef
78. Eugenol modulates the NOD1-NF-κB signaling pathway via targeting NF-κB protein in triple-negative breast cancer cells
    Xiaoyu Shi et al, 2023, Front. Endocrinol. CrossRef
79. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer
    Jiamin Guo et al, 2023, Br J Cancer CrossRef
80. Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer
    Apsana Lamsal et al, 2023, Cell Commun Signal CrossRef
81. Anti-tumor potential and mode of action of karanjin against breast cancer; an in-silico approach
    Prarambh S R Dwivedi et al, 2023, Arabian Journal of Chemistry CrossRef
82. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer
    Radwa Y. Mekky et al, 2023, Translational Oncology CrossRef
83. Fluorouracil exacerbates alpha-crystallin B chain—mediated cell migration in triple-negative breast cancer cell lines
    Lili Yang et al, 2023, Sci Rep CrossRef
84. Icariin Induces Triple-Negative Breast Cancer Cell Apoptosis and Suppresses Invasion by Inhibiting the JNK/c-Jun Signaling Pathway
    Shenghan Gao et al, 2023, DDDT CrossRef
85. Based on immune checkpoint inhibitor to improve cancer treatment
    Yijin Chen, 2023, HSET CrossRef
86. The Effect of Berberine Follow by Blue Light Irradiation and Valproic Acid on the Growth Inhibition of MDA-MB-231 Breast Cancer Cells
    Mahdieh Meschi et al, 2023, Appl Biochem Biotechnol CrossRef
87. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
    Tomomi Sanomachi et al, 2023, Front. Oncol. CrossRef
88. The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications
    Zhuoya Jiao et al, 2023, Mol Diagn Ther CrossRef
89. The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
    Stefano Zapperi et al, 2023, IJMS CrossRef
90. DNAJB4 promotes triple-negative breast cancer cell apoptosis via activation of the Hippo signaling pathway
    Fang Fang et al, 2023, Discov Onc CrossRef
91. In silico de novo drug design of a therapeutic peptide inhibitor against UBE2C in breast cancer
    Andrea Mae Añonuevo et al, 2023, J. Bioinform. Comput. Biol. CrossRef
92. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
    Reza Mehdizadeh et al, 2023, Sci Rep CrossRef
93. Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer
    Zhiwen Xu et al, 2023, Sci. Transl. Med. CrossRef
94. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer
    Jiawen Bu et al, 2023, Nat Commun CrossRef
95. Antiproliferative effects of 13α/β-steroids on triple-negative MDA-MB-231 breast cancer cells: unraveling intracellular signaling without ERα
    Alexander M. Scherbakov et al, 2023, Braz. J. Pharm. Sci. CrossRef
96. Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
    Aiswarya Chaudhuri et al, 2023, Cancers CrossRef
97. A Carrier-Free Nanomedicine Enables Apoptosis-Ferroptosis Synergistic Breast Cancer Therapy by Targeting Subcellular Organelles
    Jiaxin Zhu et al, 2023, ACS Appl. Mater. Interfaces CrossRef
98. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study
    Wei Fan et al, 2023, Tohoku J. Exp. Med. CrossRef
99. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy
    Richard W DeClue et al, 2023, Future Oncology CrossRef
100. Nonmonotone invasion landscape by noise-aware control of metastasis activator levels
     Yiming Wan et al, 2023, Nat Chem Biol CrossRef
101. Establishment of a novel cytokine-related 8-gene signature for distinguishing and predicting the prognosis of triple-negative breast cancer
     Xiaojun Liu et al, 2023, Front. Med. CrossRef
102. NFYA promotes malignant behavior of triple-negative breast cancer in mice through the regulation of lipid metabolism
     Nobuhiro Okada et al, 2023, Commun Biol CrossRef
103. Drug Target Identification in Triple Negative Breast Cancer Stem Cell Pathways: A Computational Study of Gene Regulatory Pathways Using Boolean Networks
     Aditya Lahiri et al, 2023, IEEE Access CrossRef
104. Simultaneous Delivery of Doxorubicin and EZH2‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer
     Yunshu Lu et al, 2023, Small CrossRef
105. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1/2/NF-κB pathway
     Xiaoyong Dai et al, 2023, European Journal of Pharmacology CrossRef
106. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
     Nityanand Srivastava et al, 2023, Front. Oncol. CrossRef
107. Aptamer-grafted, cell membrane-coated dendrimer loaded with doxorubicin as a targeted nanosystem against epithelial cellular adhesion molecule (EpCAM) for triple negative breast cancer therapy
     Afsana Sheikh et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
108. Future trends in advanced triple negative breast cancer
     Javier Blanco Ávila et al, 2023, Rev Cancer CrossRef
109. Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases
     Lucas E. L. Terceiro et al, 2023, IJMS CrossRef
110. Targeting nuclear hormone receptors for the prevention of breast cancer
     Cassandra L. Moyer et al, 2023, Front. Med. CrossRef
111. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer
     Lakshmi Kumari et al, 2023, Journal of Drug Targeting CrossRef
112. (R)-9bMS Inhibited the Protein Synthesis and Autophagy of Triple Negative Breast Cancer Cells via Regulating miR-4660/mTOR Axis
     Xiangdong Bai et al, 2023, PPL CrossRef
113. Inhibited Expression of NLRP12 Promotes the Development of Triple-Negative Breast Cancer by Activating the NF-κB Pathway
     Wenbin Kuang et al, 2023, Cell Biochem Biophys CrossRef
114. The calcium channel TRPC6 promotes chemotherapy-induced persistence by regulating integrin α6 mRNA splicing
     Dimpi Mukhopadhyay et al, 2023, Cell Reports CrossRef
115. Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
     Rok Gorenšek et al, 2023, BCTT CrossRef
116. Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy
     Madhu Sharma et al, 2023, Biomaterials Advances CrossRef
117. Role of Fisetin in Selected Malignant Neoplasms in Women
     Anna Markowska et al, 2023, Nutrients CrossRef
118. PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells
     Aili Saiding et al, 2023 CrossRef
119. Using anti‐PD‐L1 antibody conjugated gold nanoshelled poly (Lactic‐co‐glycolic acid) nanocapsules loaded with doxorubicin: A theranostic agent for ultrasound imaging and photothermal/chemo combination therapy of triple negative breast cancer
     Hui Jiang et al, 2023, J Biomedical Materials Res CrossRef
120. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer
     Yaru Wang et al, 2023, Biomedicine & Pharmacotherapy CrossRef
121. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease
     Qian Zhao et al, 2023, The Breast CrossRef
122. Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy
     Ketki Bhise et al, 2023, Drug Discovery Today CrossRef
123. MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
     Zinab O. Doha et al, 2023, Nat Commun CrossRef
124. The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
     Abrar Softah et al, 2023, Biomedicines CrossRef
125. Demethylase FTO inhibits the occurrence and development of triple-negative breast cancer by blocking m⁶A-dependent miR-17-5p maturation-induced ZBTB4 depletion
     Jingyi Ni et al, 2023, ABBS CrossRef
126. Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD
     Dan Luo et al, 2023, Breast Cancer Res CrossRef
127. Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance
     Song He et al, 2023, Sci Rep CrossRef
128. Drug Resistance Mechanism of Tri-ple-Negative Breast Cancer and Research Progress with DLG5
     旭升 王, 2023, ACM CrossRef
129. TNFRSF19 promotes endoplasmic reticulum stress-induced paraptosis via the activation of the MAPK pathway in triple-negative breast cancer cells
     Shiyang Liu et al, 2023, Cancer Gene Ther CrossRef
130. Non-Response of Epstein–Barr Virus-Associated Breast Cancer after Primary Chemotherapy: Report of Two Cases
     Ewgenija Gutjahr et al, 2023, Pathogens CrossRef
131. miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome
     Juana Moro et al, 2023, IJMS CrossRef
132. Compartmental Syndecan-1 (CD138) expression as a Novel Prognostic Marker in Triple-Negative Metaplastic Breast Cancer
     Yahia Ismail et al, 2023, Pathology - Research and Practice CrossRef
133. Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy
     Yan Liu et al, 2023, Journal of Colloid and Interface Science CrossRef
134. Breast Cancer Treatment: To tARget or Not? That Is the Question
     Alexandra Stone et al, 2023, Cancers CrossRef
135. Low Hospital Volume Is Associated with Higher All-Cause Mortality in Black Women with Triple Negative Breast Cancer
     Samilia Obeng-Gyasi et al, 2023, J. Racial and Ethnic Health Disparities CrossRef
136. Glutathione and acid dual-responsive nanomaterials loaded with methotrexate and magnolol for triple-negative breast cancer treatment
     Hongyi Wang et al, 2024, Materials Technology CrossRef
137. M6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer
     Xi Liu et al, 2023, Redox Biology CrossRef
138. Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer
     Meenakshi Sudhakaran et al, 2023, Cell Death Dis CrossRef
139. Self‐Promoted Targeting Delivery of Nanodrug Through Chemotherapeutic Upregulation of CD47 for Triple Negative Breast Cancer Therapy
     Qianqian Liu et al, 2023, Adv Funct Materials CrossRef
140. Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer
     Chen Zhang et al, 2023, J. Med. Chem. CrossRef
141. A Multifunctional Liposome for Synergistic Chemotherapy with Ferroptosis Activation of Triple-Negative Breast Cancer
     Jingjing Chai et al, 2023, Mol. Pharmaceutics CrossRef
142. The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors
     Suheyla Ekemen et al, 2024, BCTT CrossRef
143. Circular RNA-mediated miRNA sponge & RNA binding protein in biological modulation of breast cancer
     Jing Zhu et al, 2024, Non-coding RNA Research CrossRef
144. null
     Ouissam Al Jarroudi et al, 2023 CrossRef
145. Recent Advances in Pyrimidine-Based Drugs
     Baskar Nammalwar et al, 2024, Pharmaceuticals CrossRef
146. Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
     Wei Gao et al, 2024, PLoS ONE CrossRef
147. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer
     Chuling Hu et al, 2024, IJN CrossRef
148. Current Management of Brain Metastases in Breast Cancer
     Erkan Güler et al, 2024, Indian J Surg CrossRef
149. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift
     Mohammed N. Tantawy et al, 2024, Cancer Medicine CrossRef
150. Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy
     Lin Li et al, 2024, Chinese Chemical Letters CrossRef
151. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland
     Alireza Salem et al, 2024, Human Pathology CrossRef
152. Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives
     Honest Ndlovu et al, 2024, IJMS CrossRef
153. Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
     Yan Liang et al, 2024, Front. Pharmacol. CrossRef
154. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple‐negative breast cancer by blocking the EGFR pathway
     Rui Sang et al, 2024, Molecular Carcinogenesis CrossRef
155. Unleashing Breast Cancer Progression: miR-455-5p's Targeting of SOCS3 Drives Proliferation, Migration, and Invasion
     Xin Li et al, 2023, PPL CrossRef
156. Evolutionary Profil of Triple-Negative Breast Cancer and Influence of Histopronostic Factors: Experience of Oncology Department Chu Ibn Rochd Casablanca
     Zineb Kabala et al, 2023, EJMED CrossRef
157. “Triple-Punch” Strategy Exosome-Mimetic Nanovesicles for Triple Negative Breast Cancer Therapy
     Chenhong Zhang et al, 2024, ACS Nano CrossRef
158. Fractionation and phytochemical composition of an ethanolic extract of Ziziphus nummularia leaves: antioxidant and anticancerous properties in human triple negative breast cancer cells
     Rola Abdallah et al, 2024, Front. Pharmacol. CrossRef
159. 7-Amino-6H-anthra[9,1-cd] Isothiazol-6-one-Casein Nanosystem for Live Cell Staining and Augmenting Therapeutic Effectiveness in Triple Negative Breast Cancer
     Sajmina Khatun et al, 2024, ACS Appl. Nano Mater. CrossRef
160. Icariin exerts anti-tumor activity by inducing autophagy via AMPK/mTOR/ULK1 pathway in triple-negative breast cancer
     Mei Zhao et al, 2024, Cancer Cell Int CrossRef
161. Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion
     Jassy Mary S. Lazarte et al, 2024, Biomedicines CrossRef
162. Advancing immunotherapy in triple negative breast Cancer: A novel multimodal theranostic nanoplatform integrating synergetic ferroptosis and photothermal therapy
     Long Cheng et al, 2024, Chemical Engineering Journal CrossRef
163. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
     Aditya Bardia et al, 2024, JCO CrossRef
164. Primary adipocytes as targetable drug depot to prevent post-surgical cancer recurrence
     Yang Bo et al, 2024, Materials Today Bio CrossRef
165. STK32C modulates doxorubicin resistance in triple-negative breast cancer cells via glycolysis regulation
     Huawei Xiao et al, 2024, Mol Cell Biochem CrossRef
166. Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer
     Shanqi Li et al, 2024, J Cancer Res Clin Oncol CrossRef
167. Inhibition of NF-κB-Mediated Proinflammatory Transcription by Ru(II) Complexes of Anti-Angiogenic Ligands in Triple-Negative Breast Cancer
     Ayan Chakraborty et al, 2024, J. Med. Chem. CrossRef
168. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies
     Cristina Ferreira Almeida et al, 2024, Biochemical Pharmacology CrossRef
169. PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM
     Ting Zhou et al, 2024, Cancer Immunol Immunother CrossRef
170. Paper-Based screen-printed electrode to detect miRNA-652-5p associated to Triple-Negative Breast Cancer
     Ada Raucci et al, 2024, Electrochimica Acta CrossRef
171. Tumor Cell-Associated IL-1α Affects Breast Cancer Progression and Metastasis in Mice through Manipulation of the Tumor Immune Microenvironment
     Mathumathi Krishnamohan et al, 2024, IJMS CrossRef
172. YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer
     Xi Shen et al, 2024, Cancer Science CrossRef
173. Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model
     Pedro H. L. Viana et al, 2024, Sci Rep CrossRef
174. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis
     Zhilin Liu et al, 2024, BMC Cancer CrossRef
175. Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
     Anna Szulc et al, 2024, Cancers CrossRef
176. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
     Ann M. Chan et al, 2024, Cancers CrossRef
177. MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer
     Si Min Zheng et al, 2024 CrossRef
178. Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain
     Shuting Zuo et al, 2024, Biomaterials CrossRef
179. A Comprehensive Review on the State of the Art of Breast Cancers in Italy
     Domenico Iacopetta et al, 2024, CMC CrossRef
180. Cancer cell membrane cloaked fluorescent liposomes loaded with metal-phenolic complex nanoparticles for combinatorial therapy against breast cancer
     Paloma Patra et al, 2024, Applied Materials Today CrossRef
181. Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer
     Alyssa N. Ho et al, 2024, Cells CrossRef
182. Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer
     Meden F. Isaac-Lam, 2024, Pharmaceuticals CrossRef
183. Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview
     Erica Silvestris et al, 2024, Life CrossRef
184. Carbon nanotubes conjugated with cisplatin activate different apoptosis signaling pathways in 2D and 3D-spheroid triple-negative breast cancer cell cultures: a comparative study
     Madalina Andreea Badea et al, 2024, Arch Toxicol CrossRef
185. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer
     Zhideng Yan et al, 2024, Cancer Biology & Therapy CrossRef
186. Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6/STAT3/pentraxin 3/matrix metalloproteinase 7 axis
     Hailun Xie et al, 2024, International Immunopharmacology CrossRef
187. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
     Nating Xiong et al, 2024, Front. Oncol. CrossRef
188. null
     Alireza Bagheri et al, 2024 CrossRef
189. Glucosyltriazole amphiphile treatment attenuates breast cancer by modulating the AMPK signaling
     Neeraj Kumar Chouhan et al, 2024, Drug Development Research CrossRef
190. Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer
     Damilola Oluwalana et al, 2024, Cancer Letters CrossRef
191. Tumour-specific phosphorylation of serine 419 drives alpha-enolase (ENO1) nuclear export in triple negative breast cancer progression
     Morgan L Marshall et al, 2024, Cell Biosci CrossRef
192. Exploration of the sensitization effect of Chaihu Shugan powder on chemotherapy for triple‐negative breast cancer and its active ingredients
     Wei Wei et al, 2024, Biopolymers CrossRef
193. Identifying and Treating Those at Risk: Disparities in Rapid Relapse Among TNBC Patients in the National Cancer Database
     Saurabh Rahurkar et al, 2024, Ann Surg Oncol CrossRef
194. The Anticancer Application of Delivery Systems for Honokiol and Magnolol
     Katarzyna Dominiak et al, 2024, Cancers CrossRef
195. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts
     Lisa Nocquet et al, 2024, Sci Rep CrossRef
196. Design, synthesis, and biological studies of nitric oxide-donating piperlongumine derivatives triggered by lysyl oxidase as anti-triple negative breast cancer agents
     Yu Zou et al, 2024, Fitoterapia CrossRef
197. Inhibition of ABI2 ubiquitination-dependent degradation suppresses TNBC cell growth via down-regulating PI3K/Akt signaling pathway
     Linlin Lv et al, 2024, Cancer Cell Int CrossRef
198. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission
     Shihui Yu et al, 2024, Cell Death Dis CrossRef
199. Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial)
     Paola Tiberio et al, 2024, JPM CrossRef
200. Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K
     Rong Wang et al, 2024, Biochemical Pharmacology CrossRef
201. Diagnostic Accuracy of Combined 3.0T Magnetic Resonance Imaging and Molybdenum Target X-Ray in Triple-Negative Breast Cancer: Correlation with Prognosis in Patients Undergoing Sentinel Lymph Node Biopsy
     Li Xia et al, 2024, Women's Health Reports CrossRef
202. Isotoosendanin inhibits triple-negative breast cancer metastasis by reducing mitochondrial fission and lamellipodia formation regulated by the Smad2/3-GOT2-MYH9 signaling axis
     Jing-nan Zhang et al, 2024, Acta Pharmacol Sin CrossRef
203. A hybrid DDA/DIA-PASEF based assay library for a deep proteotyping of triple-negative breast cancer
     Petr Lapcik et al, 2024, Sci Data CrossRef
204. null
     Hannah Romano et al, 2024 CrossRef
205. Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer
     Maria George Elias et al, 2024, Cancers CrossRef
206. Potential target and mechanism exploration from α-mangostin against triple-negative breast cancer: An in silico study
     Rafly Mochamad Rivaldo et al, 2024 CrossRef
207. Conserved role of FOXC1 in TNBC is parallel to FOXA1 in ER+ breast cancer
     Revathy Ramachandran et al, 2024, iScience CrossRef
208. Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
     Maria Fernanda Imperio Pereira et al, 2024 CrossRef
209. Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis
     Mengjie Xing et al, 2024, Discov Onc CrossRef
210. High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
     Xiaohong Liao et al, 2023 CrossRef
211. Identification of Poliovirus Receptor-like 3 Protein as a Prognostic Factor in Triple-Negative Breast Cancer
     Gian Marco Leone et al, 2024, Cells CrossRef
212. Cannabinoids and triple-negative breast cancer treatment
     Luka Dobovišek et al, 2024, Front. Immunol. CrossRef
213. Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer
     Ravindra Pramod Deshpande et al, 2024, Molecular Therapy CrossRef
214. Pharmacokinetics and Bioavailability Study of a Novel Smoothened Inhibitor TPB15 for Treatment of Triple-Negative Breast Cancer in Rats by High Performance Liquid Chromatography-Mass Spectrometry
     Bo-yu Chen et al, 2024, Eur J Drug Metab Pharmacokinet CrossRef
215. Recent Advances in Immunotherapy for Breast Cancer: A Review
     Qian-Er Wen et al, 2024, BCTT CrossRef
216. The anti‐tumor effects of cosmosiin through regulating AhR/CYP1A1‐PPARγ in breast cancer
     Dan Wang et al, 2024, The FASEB Journal CrossRef
217. A Prognostic Risk Signature of Two Autophagy-Related Genes for Predicting Triple-Negative Breast Cancer Outcomes
     Bing Yu et al, 2024, BCTT CrossRef
218. Development of Dual-Targeted Mixed Micelles Loaded with Celastrol and Evaluation on Triple-Negative Breast Cancer Therapy
     Siying Huang et al, 2024, Pharmaceutics CrossRef
219. Triple-Negative Papillary Carcinoma of the Breast: A Case Report
     Abdulrahman Karmach et al, 2024 CrossRef